The long-term results of a phase II trial evaluating neoadjuvant gemcitabine, nab-paclitaxel, and S1 treatment in borderline resectable pancreatic cancer with arterial contact (BRPC-A) show promising outcomes. Of the 47 patients, 96% underwent pancreatectomy, and the updated median overall survival was 41.0 months with 2- and 5-year survival rates of 68.0% and 44.6%, respectively. Tumor diameter reduction and CA19-9 reduction after neoadjuvant chemotherapy, as well as no lymph node metastasis, no major surgical complications, and completion of adjuvant chemotherapy, were associated with improved survival.
Journal Article by Uemura K, Kondo N (…) Takahashi S et 7 al. in J Hepatobiliary Pancreat Sci
© 2023 Japanese Society of Hepato-Biliary-Pancreatic Surgery.